MY141780A - 5-substituted quinoline and isoquinoline derivatives, a method for the production thereof and their use as antiphlogistics - Google Patents

5-substituted quinoline and isoquinoline derivatives, a method for the production thereof and their use as antiphlogistics

Info

Publication number
MY141780A
MY141780A MYPI20055308A MYPI20055308A MY141780A MY 141780 A MY141780 A MY 141780A MY PI20055308 A MYPI20055308 A MY PI20055308A MY PI20055308 A MYPI20055308 A MY PI20055308A MY 141780 A MY141780 A MY 141780A
Authority
MY
Malaysia
Prior art keywords
antiphlogistics
production
substituted quinoline
isoquinoline derivatives
isoquinoline
Prior art date
Application number
MYPI20055308A
Inventor
Stefan Jaroch
Werner Skuballa
Hartmut Rehwinkel
Norbert Schmees
Heike Schaecke
Jan Huebner
Orlin Petrov
Matthias Schneider
Christian Dinter
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102005020331A external-priority patent/DE102005020331A1/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MY141780A publication Critical patent/MY141780A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOUNDS OF GENERAL FORMULA (IIA) OR (IIB) AND THEIR USE AS PHARMACEUTICAL AGENTS.
MYPI20055308A 2004-11-12 2005-11-11 5-substituted quinoline and isoquinoline derivatives, a method for the production thereof and their use as antiphlogistics MY141780A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004055633A DE102004055633A1 (en) 2004-11-12 2004-11-12 New 5-substituted quinoline and isoquinoline derivatives are glucocorticoid receptor binders useful for treating inflammatory diseases e.g. alveolitis, Sjogren's syndrome, atopic dermatitis, acute lymphatic leukemia, rhinitis and emesis
DE102005020331A DE102005020331A1 (en) 2005-04-26 2005-04-26 New 5-substituted quinoline and isoquinoline derivatives are glucocorticoid receptor binders useful for treating inflammatory diseases e.g. alveolitis, Sjogren's syndrome, atopic dermatitis, acute lymphatic leukemia, rhinitis and emesis

Publications (1)

Publication Number Publication Date
MY141780A true MY141780A (en) 2010-06-30

Family

ID=35613753

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20055308A MY141780A (en) 2004-11-12 2005-11-11 5-substituted quinoline and isoquinoline derivatives, a method for the production thereof and their use as antiphlogistics

Country Status (30)

Country Link
EP (1) EP1844039B1 (en)
JP (1) JP4460608B2 (en)
KR (1) KR101168462B1 (en)
CN (1) CN101124220B (en)
AR (1) AR051767A1 (en)
AU (1) AU2005303926B2 (en)
BR (1) BRPI0517797A (en)
CA (1) CA2586689C (en)
CY (1) CY1110520T1 (en)
DE (2) DE102004055633A1 (en)
DK (1) DK1844039T3 (en)
EA (1) EA013076B1 (en)
ES (1) ES2329599T3 (en)
GT (1) GT200500330A (en)
HR (1) HRP20090509T1 (en)
IL (1) IL182933A (en)
ME (2) MEP13608A (en)
MX (1) MX2007005736A (en)
MY (1) MY141780A (en)
NO (1) NO332405B1 (en)
NZ (1) NZ555064A (en)
PA (1) PA8652701A1 (en)
PE (1) PE20061052A1 (en)
PL (1) PL1844039T3 (en)
PT (1) PT1844039E (en)
RS (2) RS51161B (en)
SI (1) SI1844039T1 (en)
TW (1) TWI311559B (en)
UY (1) UY29213A1 (en)
WO (1) WO2006050998A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
TWI464148B (en) 2006-03-16 2014-12-11 Evotec Us Inc Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
BRPI0714155A2 (en) * 2006-07-07 2012-12-25 Bausch & Lomb use of a dissociated glucocorticoid receptor agonist (digra), a prodrug thereof, or a pharmaceutically acceptable salt thereof
AU2007284176B2 (en) * 2006-08-07 2013-03-28 Bausch & Lomb Incorporated Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases
SG174031A1 (en) * 2006-08-07 2011-09-29 Bausch & Lomb Treating infections and sequelae thereof with combined dissociated' glucocorticoid receptor agonists and anti-infective agents
PL2056799T3 (en) * 2006-08-31 2014-01-31 Bausch & Lomb Compositions and methods for treating or preventing glaucoma or progression thereof
CA2661197C (en) * 2006-09-11 2012-01-03 Bausch & Lomb Incorporated Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
US20110105559A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy
US20110104159A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
AU2007319590A1 (en) * 2006-11-09 2008-05-22 Bausch & Lomb Incorporated Synthesis of selected stereoisomers of certain substituted alcohols
EP1982976A1 (en) * 2007-04-18 2008-10-22 Intendis GmbH Process for the manufacture of non-steroidal anti-inflammatory agents and intermediates thereof
CA2683512C (en) * 2007-04-18 2014-12-02 Intendis Gmbh Process for the manufacture of non-steroidal anti-inflammatory agents and intermediates thereof
EP2016935A1 (en) * 2007-07-09 2009-01-21 Intendis GmbH Pharmaceutical composition for topical application of poorly soluble compounds
US20090042936A1 (en) * 2007-08-10 2009-02-12 Ward Keith W Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation
US20090087443A1 (en) * 2007-09-27 2009-04-02 Bartels Stephen P Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery
KR20100072333A (en) * 2007-11-01 2010-06-30 보오슈 앤드 롬 인코포레이팃드 Non-aqueous water-miscible materials as vehicles for drug delivery
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
CN101983961B (en) * 2010-11-24 2012-05-09 浙江启明生化科技有限公司 Preparation method of 5-amino-2-methylquinoline
US20120316199A1 (en) 2011-06-07 2012-12-13 Ward Keith W Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain
WO2017137375A1 (en) 2016-02-12 2017-08-17 Bayer Animal Health Gmbh Mapracorat for use in the treatment of canine dermatitis
CN111732493B (en) * 2017-01-16 2023-01-24 宜昌尚诺德生物医药科技有限公司 Synthesis process of arylamine compound
ES2980934T3 (en) 2019-01-22 2024-10-03 Akribes Biomedical Gmbh Selective glucocorticoid receptor modifiers for treating impaired wound healing in the skin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4041482A1 (en) * 1990-12-22 1992-06-25 Boehringer Ingelheim Kg NEW PHARMACEUTICAL USE OF CARBOCYCLIC AND HETEROCYCLICALLY ANNELATED DIHYDROPYRIDINE
NO940245D0 (en) * 1993-01-28 1994-01-24 Takeda Chemical Industries Ltd Quinoline or quinazoline derivatives, their preparation and use
RU2127271C1 (en) * 1997-03-13 1999-03-10 Пермская государственная фармацевтическая академия 2-chloro-5,6,7,8-tetrahydroquinoline-4-carboxylic acid 5-nitrofurfurylidene hydrazide eliciting an antibacterial activity
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
DE10215316C1 (en) * 2002-04-02 2003-12-18 Schering Ag Quinoline and isoquinoline derivatives, a pharmaceutical agent and their use as anti-inflammatory agents
CA2512257A1 (en) * 2003-01-03 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
US20040224992A1 (en) * 2003-02-27 2004-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7179919B2 (en) * 2004-03-18 2007-02-20 Boehringer Ingelheim Pharmaceuticals, Inc. Stereoselective synthesis of certain trifluoromethyl-substituted alcohols

Also Published As

Publication number Publication date
KR20070084192A (en) 2007-08-24
MEP13608A (en) 2010-06-10
CY1110520T1 (en) 2015-04-29
PT1844039E (en) 2009-10-19
KR101168462B1 (en) 2012-07-27
IL182933A0 (en) 2007-09-20
SI1844039T1 (en) 2009-12-31
PA8652701A1 (en) 2006-07-03
JP2008519803A (en) 2008-06-12
HK1112243A1 (en) 2008-08-29
CA2586689C (en) 2012-04-17
PE20061052A1 (en) 2006-11-08
TWI311559B (en) 2009-07-01
UY29213A1 (en) 2006-05-31
RS51161B (en) 2010-10-31
PL1844039T3 (en) 2009-12-31
JP4460608B2 (en) 2010-05-12
CA2586689A1 (en) 2006-05-18
RS20070205A (en) 2008-11-28
GT200500330A (en) 2006-09-21
EA200700982A1 (en) 2007-10-26
DK1844039T3 (en) 2009-11-09
AU2005303926A1 (en) 2006-05-18
IL182933A (en) 2011-10-31
AU2005303926B2 (en) 2011-05-19
ES2329599T3 (en) 2009-11-27
ME00155B (en) 2010-10-10
CN101124220B (en) 2012-04-25
EP1844039A1 (en) 2007-10-17
NZ555064A (en) 2009-09-25
NO20072963L (en) 2007-08-03
NO332405B1 (en) 2012-09-10
AR051767A1 (en) 2007-02-07
BRPI0517797A (en) 2008-10-21
CN101124220A (en) 2008-02-13
WO2006050998A1 (en) 2006-05-18
DE102004055633A1 (en) 2006-05-18
MX2007005736A (en) 2007-09-07
HRP20090509T1 (en) 2009-11-30
EP1844039B1 (en) 2009-07-15
EA013076B1 (en) 2010-02-26
TW200640913A (en) 2006-12-01
DE502005007725D1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
MY141780A (en) 5-substituted quinoline and isoquinoline derivatives, a method for the production thereof and their use as antiphlogistics
GEP20105024B (en) Fused heterocyclic compound
SI1881967T1 (en) Substituted benzo(d)isoxazol-3-yl amine compounds as analgesics
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
MY148491A (en) FUSED BICYCLIC mTOR INHIBITORS
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
WO2006028958A3 (en) Pyridyl inhibitors of hedgehog signalling
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
WO2005021544A3 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
MX2007003108A (en) Substituted bicyclic imidazo-3-ylamine compounds.
TNSN08191A1 (en) Kinase inhibitors
AP2321A (en) Quinoline derivatives for use as mycobactrial inhibitor.
TW200624426A (en) BACE inhibitors
WO2006047528A3 (en) Pyrazolobenzamides and derivatives as factor xa inhibitors
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
ZA200801332B (en) Pentacyclic kinase inhibitors
TW200639156A (en) New compounds
PL1888514T3 (en) Salts of substituted allophanates and their use in drugs
TW200619205A (en) A method for preparing irbesartan and intermediates thereof
TW200634013A (en) Quinoline derivative, its use, production and pharmaceutical agents containing the derivative
TW200612942A (en) Thiazolinone unsubstituted quinolines
MX2007007480A (en) Chroman derivatives and their use as 5-ht receptor ligands.
MX2007003911A (en) Benzoxazine and quinoxaline derivatives and uses.
PT1706383E (en) Amine salt of carbostyril derivative useful for the treatment of, inter alia, gastric ulcer